Wellgistics Health Inc. Common Stock (WGRX)
FairStock Score: 27/100 — RISKY
Key Financials
| Current Price | $3.03 |
| Market Cap | $17M |
| P/E Ratio | -0.07 |
| ROE | —% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
I look for businesses that earn good returns on capital, generate cash, and sell at a sensible price. Wellgistics Health fails most of those tests. In the latest reported quarter, fiscal Q2 2026, revenue was $1.8 million and net income was negative $18.4 million, a net margin of -1031.72%. The provided revenue-growth figure is -85.64%, so the top line is contracting violently. The provided profit-growth figure is 76.13%, but that is cold comfort when the quarter still lost $18.4 million. FairStock's calculated trailing P/E is -0.07 at the 2026-07-29 close, and the provided EPS is -$44.00, meaning there is no earnings-based valuation to anchor the $3.03 share price. Free cash flow for the trailing twelve months was negative $14.7 million, a FairStock FCF yield of -88.1% against a $16.6 million market cap. Return on capital employed is -79.18%, the Piotroski F-Score is 3/9, the Altman Z-Score is -7.59, and the overall FairStock Score is 27/100, all of which point to severe financial distress. Medical distribution can be a scale business, but there is no evidence here of scale, pricing power, or a durable moat. The Lynch category is none because there are only 0 years of filed annual results, not the 3 needed. At $3.03, this is not a Graham-style bargain; it is a speculative bet on survival.
In plain English: Wellgistics Health distributes prescription and over-the-counter medicines to pharmacies and manufacturers. The business looks very weak right now: in its latest reported quarter, fiscal Q2 2026, it had $1.8 million of revenue but lost $18.4 million, and it used $14.7 million of cash over the past year. At $3.03 a share, the price does not look supported by current profits or cash flow; it looks speculative.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-07-29 close · note generated 2026-10-15 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer